Clinical Trials Logo
  1. Home
  2. Eosinophilic Gastroenteritis
  3. NCT04856891

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis — EoDyssey  

Eosinophilic Gastroenteritis Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Duodenitis Who Have an Inadequate Response With, Lost Response to, or Were Intolerant to Standard Therapies

Clinical Trial Summary

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04856891
Study type Interventional
Source Allakos Inc.
Contact
Status Completed
Phase Phase 3
Start date May 20, 2021
Completion date January 9, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03320369 - Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis N/A
Completed NCT00148603 - Montelukast in the Treatment of Duodenal Eosinophilia N/A
Completed NCT03664960 - An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis Phase 2
Completed NCT00267475 - Data Bank for Eosinophilic Disorders N/A
Active, not recruiting NCT03678545 - Dupilumab in Eosinophilic Gastritis Phase 2
Terminated NCT01814059 - Sirolimus for Eosinophil-Associated Gastrointestinal Disorders Phase 1
Active, not recruiting NCT05214768 - A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT03496571 - A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2
Recruiting NCT02523118 - OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Completed NCT05251909 - Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) Phase 3
Completed NCT05439772 - Examining the Effect of Ondansetron on Bowel Prep Success Phase 4
Completed NCT00266565 - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Phase 1/Phase 2
Recruiting NCT05199532 - Eosinophilic Gastrointestinal Disorders Registry
Terminated NCT01212016 - Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders N/A
Completed NCT02897271 - Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort